MIRA Pharmaceuticals, Inc. (MIRA)

Market Cap	21.06M
Revenue (ttm)	n/a
Net Income (ttm)	-7.92M
Shares Out	16.92M
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	76,588
Open	1.220
Previous Close	1.210
Day's Range	1.220 - 1.250
52-Week Range	0.510 - 5.010
Beta	n/a
Analysts	Strong Buy
Price Target	14.00 (+1,024.5%)
Earnings Date	Aug 12, 2025

About MIRA

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutica...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Aug 3, 2023
• Employees: 3
• Stock Exchange: NASDAQ
• Ticker Symbol: MIRA
• Website: https://mirapharmaceuticals.com

Analyst Forecast

According to 2 analysts, the average rating for MIRA stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 1,024.50% from the latest price.

Price Target

$14.0

(1,024.50% upside)

Analyst Consensus: Strong Buy